Clinical Trial Details
| Trial ID: | L4030 |
| Source ID: | NCT00280046 |
| Associated Drug: | Biphasic Insulin Aspart |
| Title: | Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart |
| Outcome Measures: | Primary: HbA1c, after 16 weeks of treatment | Secondary: Self-measured 7-point capillary plasma glucose profile|Change in body weight|Incidence of hypoglycaemic episodes and adverse events|Quality of Life |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 307 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2003-11 |
| Completion Date: | 2004-07 |
| Results First Posted: | |
| Last Update Posted: | 2017-01-06 |
| Locations: | Novo Nordisk Investigational Site, Arkhangelsk, 163045, Russian Federation|Novo Nordisk Investigational Site, Belgorod, 308007, Russian Federation|Novo Nordisk Investigational Site, Ekaterinburg, 620102, Russian Federation|Novo Nordisk Investigational Site, Kazan, 420064, Russian Federation|Novo Nordisk Investigational Site, Khabarovsk, 680067, Russian Federation|Novo Nordisk Investigational Site, Nizhniy Novgorod, 603126, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, 630090, Russian Federation|Novo Nordisk Investigational Site, Omsk, 644070, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194291, Russian Federation|Novo Nordisk Investigational Site, Vladivostok, 690105, Russian Federation|Novo Nordisk Investigational Site, Voronezh, 394053, Russian Federation |
| URL: | https://clinicaltrials.gov/show/NCT00280046 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|